NCT07710183 Pumpkin Seed Oil as a Nutraceutical for Hemodialysis Patients
| NCT ID | NCT07710183 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Al-Mustansiriyah University |
| Condition | End Stage Renal Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-07-20 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-07-20 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with end-stage renal disease (ESRD) on maintenance hemodialysis experience chronic systemic inflammation, oxidative stress, and dyslipidemia, which together drive much of the excess cardiovascular morbidity and mortality seen in this population. Pumpkin seed oil is a nutraceutical rich in polyunsaturated fatty acids, phytosterols,and tocopherols, with documented antioxidant, anti-inflammatory, and antihyperlipidemic properties in preclinical and limited clinical studies. This study investigates the potential role of pumpkin seed oil as a nutraceutical on the clinical and biochemical outcomes of hemodialysis patients. It is a randomized, open-label, prospective interventional study in which daily oral supplementation with pumpkin seed oil (1000 mg once daily) for 3 months is evaluated against usual care. Eighty-five participants will be assigned to either an intervention group (n=45, pumpkin seed oil 1000 mg/day plus usual care) or a control group (n=40, usual care only). The biochemical outcomes assessed are changes in serum interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), lipid profile, malondialdehyde (MDA), and superoxide dismutase (SOD) from baseline to the end of the 3-month follow-up period. The study is being conducted at the Hemodialysis Center, Al-Karama Teaching Hospital, Iraq
Eligibility Criteria
Inclusion Criteria: * End-stage renal disease (ESRD) on hemodialysis for more than 6 months, on a constant dialysis program. * Hemodynamically stable (no recent hospitalization for infections, cardiovascular events, or major surgery within the past 3 months). * No active acute infections. * Serum albumin ≥ 3.0 g/dL. Exclusion Criteria: * Regular intake of dietary supplements (e.g., omega-3, antioxidants) for at least one month prior to enrollment. * Autoimmune disease, liver disease, cancer, or acquired immunodeficiency syndrome (AIDS). * Known sensitivity/allergy to pumpkin seed oil. * Current use of lipid-lowering agents. * Diabetes mellitus. * Current use of anticoagulants (warfarin, direct oral anticoagulants). * Current use of immunosuppressants, corticosteroids, or anti-inflammatory drugs. * Pregnant or breastfeeding women. * Residual kidney function (urine output \> 200 mL/day).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07710183 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying End Stage Renal Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07710183 currently recruiting?
Yes, NCT07710183 is actively recruiting participants. Contact the research team at pharm.drmhdclinical@uomustansiriyah.edu.iq for enrollment information.
Where is the NCT07710183 trial being conducted?
This trial is being conducted at Baghdad, Iraq.
Who is sponsoring the NCT07710183 clinical trial?
NCT07710183 is sponsored by Al-Mustansiriyah University. The trial plans to enroll 100 participants.